Data Insights

Olaparib by AstraZeneca for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase I for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

Olaparib by AstraZeneca for Osteosarcoma: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Osteosarcoma

Data Insights

Olaparib by AstraZeneca for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Olaparib by AstraZeneca for Bone Sarcoma: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Bone Sarcoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Bone Sarcoma

Data Insights

Olaparib by AstraZeneca for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

Data Insights

Olaparib by AstraZeneca for Pancreatic Cancer: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Pancreatic Cancer

Data Insights

Olaparib by AstraZeneca for Metastatic Uveal Melanoma: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Metastatic Uveal Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Metastatic Uveal Melanoma

Data Insights

Olaparib by AstraZeneca for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Squamous Non-Small Cell Lung Cancer

Data Insights

Olaparib by AstraZeneca for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Pancreatic Ductal Adenocarcinoma

Data Insights

Olaparib by AstraZeneca for Pulmonary Arterial Hypertension: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Pulmonary Arterial Hypertension. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Pulmonary Arterial Hypertension

Data Insights

Olaparib by AstraZeneca for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

Olaparib by AstraZeneca for Liposarcoma: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Liposarcoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Liposarcoma

Data Insights

Olaparib by AstraZeneca for Non-Hodgkin Lymphoma: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Non-Hodgkin Lymphoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Non-Hodgkin Lymphoma

Data Insights

Olaparib by AstraZeneca for Glioma: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Glioma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Glioma

Data Insights

Olaparib by AstraZeneca for Neuroblastoma: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Neuroblastoma

Data Insights

Olaparib by AstraZeneca for Soft Tissue Sarcoma: Likelihood of Approval

Olaparib is under clinical development by AstraZeneca and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Soft Tissue Sarcoma